AMENDMENT NO. 2 TO SCHEDULE 13D
This amendment to Schedule 13D is being filed by Access Industries Holdings LLC (AIH), Access Industries Management, LLC
(AIM), Access Industries, LLC (Access LLC), Clal Biotechnology Industries Ltd. (CBI) and Len Blavatnik (collectively, the Reporting Persons, and each, a Reporting Person) relating to the
American Depositary Shares, no par value (ADSs), evidenced by American Depositary Receipts, each of which represents five ordinary shares, no par value per share (the Ordinary Shares), of Anchiano Therapeutics Ltd. (the
Issuer). As a result of CBIs relationships with the other Reporting Persons, it is possible that CBI may be deemed a member of a group, within the meaning of Rule 13d-5(b)(1)
under the Securities Exchange Act of 1934, as amended (the Exchange Act), with such other Reporting Persons. CBI is making this filing as a precautionary matter and this filing shall not be deemed an admission that CBI is a member of a
group or is subject to the reporting requirements of Section 13 of the Exchange Act.
The Schedule 13D filed with the Securities and
Exchange Commission on February 21, 2019 (the Schedule), as amended and supplemented by Amendment No. 1 filed on December 31, 2019, is hereby amended and supplemented by the Reporting Persons as set forth below in this
Amendment No. 2. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that has
materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not
defined herein have the respective meanings assigned to them in the Schedule.
Item 4 Purpose of Transaction
The disclosure in Item 4 is hereby amended to add the following to the end thereof:
As previously disclosed by the Issuer, on January 9, 2020, Michael Rice informed the Board of his decision to withdraw his name from
consideration for appointment to the Board as a designee of CBI.
On January 10, 2020, the Issuer notified CBI that it would nominate
two additional designees of CBI for election to the Board at the Issuers annual general meeting. CBI has reiterated its request that the Issuer reconstitute the membership of the Board on a basis consistent with its demand letter, dated
December 27, 2019, as expeditiously as possible and continues to evaluate and consider its options in this regard.
Item 7 Materials to Be
Filed as Exhibits
|
|
|
Exhibit |
|
Description |
|
|
99.9 |
|
Joint Filing Agreement, dated as of January 13, 2020. |